In a multicenter study of 232 patients with stage IV HER2-positive gastric cancer, conversion surgery following trastuzumab-based chemotherapy and immunotherapy yielded significantly improved outcomes. Patients who underwent the procedure experienced median progression-free survival of 37.7 months and overall survival of 50.9 months. In contrast, those who did not have surgery had progression-free survival of 10.8 months and overall survival of 22.0 months. These findings support the efficacy of surgical intervention for select patients.
Journal Article by Liang H, Liang C (…) Zhao L et 6 al. in Ann Surg Oncol
© 2025. Society of Surgical Oncology.